HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Oropharyngeal Neoplasms

Subscribe to New Research on Oropharyngeal Neoplasms

Tumors or cancer of the OROPHARYNX.

Also Known As:

Cancer of the Oropharynx; Neoplasms, Oropharyngeal; Oropharynx Cancer; Oropharynx Neoplasms; Cancer, Oropharyngeal; Cancer, Oropharynx; Cancers, Oropharyngeal; Cancers, Oropharynx; Neoplasm, Oropharyngeal; Neoplasm, Oropharynx; Neoplasms, Oropharynx; Oropharnyx Cancer; Oropharnyx Cancers; Oropharyngeal Cancers; Oropharyngeal Neoplasm; Oropharynx Cancers; Oropharynx Neoplasm; Cancer of Oropharnyx; Oropharyngeal Cancer

Networked: 590 relevant articles (41 outcomes, 97 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Head and Neck Neoplasms (Head and Neck Cancer)
3.	Laryngeal Neoplasms (Laryngeal Cancer)
4.	Xerostomia
5.	Hypopharyngeal Neoplasms

Experts

1.	Sturgis, Erich M: 13 articles (11/2015 - 07/2005)
2.	Wei, Qingyi: 11 articles (11/2015 - 07/2005)
3.	Eisbruch, Avraham: 11 articles (08/2014 - 12/2004)
4.	Langendijk, Johannes A: 10 articles (11/2013 - 09/2005)
5.	Li, Guojun: 8 articles (11/2015 - 03/2010)
6.	Garden, Adam S: 8 articles (01/2015 - 07/2005)
7.	Kovács, Adorján F: 8 articles (01/2015 - 01/2002)
8.	Chepeha, Douglas B: 8 articles (08/2014 - 01/2007)
9.	Leemans, C René: 8 articles (07/2013 - 09/2005)
10.	O'Sullivan, Brian: 7 articles (10/2015 - 01/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Oropharyngeal Neoplasms:

1.	Papillomavirus Vaccines (HPV Vaccines)IBA 10/01/2014 - "Licensed human papillomavirus (HPV) vaccines provide near complete protection against the types of HPV that most commonly cause anogenital and oropharyngeal cancers (HPV 16 and 18) when administered to individuals naive to these types. " 07/01/2014 - "However, HPV vaccines are presently not recommended for preventing oropharyngeal cancer (OPC), although they have been shown to be highly effective against the HPV strains that are most commonly found in the oropharynx. " 11/12/2013 - "However, HPV vaccines are presently not recommended for preventing oropharyngeal cancer, although they have been shown to be highly effective against the HPV strains that are most commonly found in the oropharynx. " 07/01/2012 - "If proven efficacious, currently available prophylactic HPV vaccines hold great promise for primary prevention of HPV-associated oropharyngeal cancers." 08/01/2011 - "Dental health care personnel (DHCP) should be knowledgeable about the role of HPV in carcinogenesis, the association of HPV with oropharyngeal cancers and HPV vaccines, and they should be prompt in referring patients with suggestive symptoms for evaluation. "
2.	Cisplatin (Platino)FDA LinkGeneric 04/01/2014 - "Weekly cisplatin in the adjuvant setting may be a better treatment for patients with HPV-positive oropharynx cancer to preserve survival and minimize toxicity." 04/01/2014 - "Patients with HPV/p16-positive oropharynx cancer who received adjuvant chemoradiation therapy with high-dose and weekly cisplatin had three-year overall survival rates of 91% and 86% (p=0.56), and 3-year recurrence free survival of 84% and 82% (p=0.93). " 04/01/2012 - "The effect of intraarterial high-dose cisplatin on lymph nodes in oral and oropharyngeal cancer." 09/20/2010 - "HPV-associated oropharyngeal cancer is a distinct entity with a favorable prognosis compared with HPV-negative oropharyngeal cancer when treated with cisplatin-based chemoradiotherapy." 02/01/2010 - "Concurrent chemoradiation with carboplatin-5-fluorouracil versus cisplatin in locally advanced oropharyngeal cancers: is more always better?"
3.	Fluorouracil (Carac)FDA LinkGeneric 05/01/2015 - "HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer." 10/01/2015 - "In order to treat the primary site without resection, superselective intra-arterial infusions with DCF anterogradely and 60 mg/m2 of DOC and 60 mg/m2 of CDDP via the femoral artery on day 1 were administered, followed by continuous intravenous instillation of 750 mg/m2/day of 5-FU for 5 days from day 2. The 5- year survival rate was 70.4% in laryngeal cancer, 72.8% in oropharyngeal cancer, and 68.5% in hypopharyngeal cancer. " 01/01/2008 - "The objective of this study was to prepare and evaluate in vitro the bioadhesive gels of 5-Fluorouracil (FU) for the treatment of oropharyngeal cancer. " 03/01/2007 - "A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients." 10/01/2003 - "In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index. "
4.	Interleukin-2 (IL2)IBA 03/01/1989 - "Most prominent was the significant reduction in IL-2 release of patients with cancer of the oropharynx and in patients with positive lymph nodes in the neck. " 02/01/1989 - "In patients with cancer of the oropharynx, a significant reduction in the IL-2 secretion was observed when compared with the larynx cancer group or with healthy donors. " 10/01/2011 - "IL-2 +114 G/T was a predictor of poor survival in oral cavity/oropharynx cancer and larynx cancer (HR = 1.32; 95%CI = 0.61-2.85). " 10/01/2011 - "IL-2 -384 G/T was associated with better survival in oral cavity/oropharynx cancer (HR = 0.80; 95%CI = 0.45-1.42) and hypopharynx cancer (HR = 0.68; 95%CI = 0.21-2.20), but an inverse relationship was observed for larynx cancer. "
5.	Carboplatin (JM8)FDA LinkGeneric 01/01/2007 - "Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: seven-year follow-up of a phase II trial." 01/01/2012 - "For adjuvant radiochemotherapy of patients with locally advanced cancer of the oropharynx and oral cavity, cisplatin appears preferable to carboplatin as it resulted in better outcomes without increased toxicity." 01/01/2014 - "The was a prospective study of 72 patients with stage III to IV oropharyngeal cancer treated definitively with intensity-modulated radiotherapy (IMRT) concurrent with weekly carboplatin and paclitaxel. " 03/01/2002 - "Our present results demonstrated impressive clinical and pathological response rates of concurrent Taxol/carboplatin and radiotherapy as a preoperative treatment modality in advanced oral and oropharyngeal cancer." 10/01/1999 - "Our preliminary results demonstrated excellent clinical and pathological response rates of concurrent Taxol/carboplatin and radiotherapy as preoperative treatment modality in advanced oral and oropharyngeal cancer."
6.	docetaxel (Taxotere)FDA Link 01/01/2005 - "To examine the feasibility and efficacy of weekly docetaxel with concurrent radiation as postoperative treatment in a multimodality approach to oral and oropharyngeal cancer. " 01/01/2005 - "Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer." 01/01/2005 - "Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival. " 03/01/2007 - "[Planned neck dissection after weekly docetaxel and concurrent radiotherapy for advanced oropharyngeal cancer]." 04/01/2002 - "Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study."
7.	RetinoidsIBA 09/01/2002 - "With respect to the clinical efficacy of retinoids some positive effects have been observed in early stage oral and oropharyngeal cancer. " 09/01/2002 - "This review gives an update on the role of retinoids in oral and oropharyngeal cancer and their precursor lesions. " 07/01/1993 - "These include extensive programs of behavior modification such as smoking cessation and studies of synthetic retinoids and other chemopreventative agents in head and neck cancers, esophageal cancer, and other oropharyngeal cancers. " 02/15/1993 - "Retinoids have a potential for impacting on the treatment of neoplasms such as promyelocytic leukemia and oropharyngeal cancers. "
8.	arginylarginine (Arg-Arg)IBA 12/01/2010 - "Stratification analyses showed that a reduced risk associated with the -606CC genotype was more pronounced in subgroups of non-smokers, non-drinkers, younger subjects (defined as ≤57 years), carriers of the TP53 Arg/Arg (rs1042522) genotype, patients with oropharyngeal cancer or late-stage SCCHN. " 01/01/2012 - "The results from this study showed both p53 variant genotypes (Arg/Pro+Pro/Pro) and p73 variant genotypes (GC/AT+AT/AT) were significantly associated with HPV16-positive tumor in oropharyngeal cancer patients (OR, 1.9, 95% CI, 1.1-3.3 and OR, 2.1, 95% CI, 1.2-3.8, respectively), while the combined variant genotypes (p53 Pro carriers and p73 AT carriers) exhibited a significantly greater association with HPV16-positive tumor (OR, 3.2, 95% CI, 1.4-7.4), compared with combined wild-type genotypes (p53 Arg/Arg and p73 GC/GC), and the association was in a statistically significant dose-effect relationship (p = 0.001). "
9.	AK 2123IBA 10/01/2006 - "Safety and radiosensitizing efficacy of sanazole (AK 2123) in oropharyngeal cancers: randomized controlled double blind clinical trial." 10/01/2006 - "The study validates the usefulness of sanazole for initial loco-regional control in oropharyngeal cancers."
10.	AntibodiesIBA 04/01/2014 - "The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. " 04/01/2014 - "Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. " 04/17/2013 - "HPV16 E6 antibodies are strongly associated with HPV16-related oropharyngeal cancers. " 07/01/2015 - "HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status." 04/01/2014 - "Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. "

Therapies and Procedures

1.	Radiotherapy 01/01/2004 - "The changes in treatment approach for oral and oropharyngeal cancer over the last 5 decades, with an increase of surgical treatment and its combination with radiotherapy significantly improved the survival rates." 01/01/2010 - "Altered fractionation radiotherapy is associated with an improvement in overall survival and locoregional control in patients with oral cavity and oropharyngeal cancers. " 01/01/2009 - "Oropharyngeal cancers in those without a history of tobacco abuse may be biologically different and more amenable to cure with radiotherapy." 03/01/2015 - "Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy." 06/01/2013 - "To test the toxicity and efficacy of concomitant boost radiotherapy alone against concurrent chemoradiation (conventional fractionation) in locally advanced oropharyngeal cancer in our patient population. "
2.	Drug Therapy (Chemotherapy) 01/01/2010 - "The proportion of participants in each trial with oral cavity and oropharyngeal cancers are recorded in Additional Table 1. There was no statistically significant improvement in overall survival associated with induction chemotherapy compared to locoregional treatment alone in 25 trials (hazard ratio (HR) of mortality 0.92, 95% confidence interval (CI) 0.84 to 1.00). " 01/01/2001 - "However, in those with oropharyngeal cancer, both primary control and survival were significantly improved when chemotherapy was used. " 03/01/1995 - "To evaluate the feasibility and efficacy of a strategy using induction chemotherapy followed by radiation therapy (RT) as a means of organ-function preservation in patients with advanced oropharynx cancer. " 10/10/2015 - "Although the use of radiation with or without chemotherapy to treat oropharyngeal cancer (OPC) is supported by evidence from prospective clinical trials, there are no prospective data supporting the use of this new surgical approach for OPC. " 08/01/2014 - "To describe voice and speech quality changes and their predictors in patients with locally advanced oropharyngeal cancer treated on prospective clinical studies of organ-preserving chemotherapy-intensity modulated radiation therapy (chemo-IMRT). "
3.	Enteral Nutrition (Feeding, Tube) 09/01/2015 - "Response to: "No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer"." 09/01/2015 - "No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer." 05/01/2013 - "The purpose of this study is to determine the pre-treatment clinical factors associated with prolonged enteral feeding in patients with oropharyngeal cancer treated with chemoradiation. " 11/01/2013 - "Almost 40% of patients with oropharyngeal cancer treated with nonsurgical organ preservation modalities may avoid feeding tube placement. " 05/01/2012 - "To determine the outcomes of patients managed with different routes of enteral feeding during chemoradiotherapy for oropharynx cancer. "
4.	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 06/01/2009 - "Ten randomly selected patients with oropharyngeal cancer, primarily treated by intensity-modulated radiotherapy (IMRT), were included in this study. " 10/01/2008 - "Ten oropharyngeal cancer patients with a contralateral elective PTV were included in this planning study, using intensity modulated radiotherapy (IMRT). " 01/15/2015 - "Severe swallowing dysfunction necessitating enteral support is a well known late sequela of nonsurgical therapy for oropharyngeal cancer, but its incidence after intensity-modulated radiotherapy has not been quantified comprehensively outside of small single-institution series. " 09/01/2014 - "To demonstrate the comparative effectiveness of transoral robotic surgery (TORS) to intensity modulated radiotherapy (IMRT) for early T-stage oropharyngeal cancer. " 11/01/2013 - "To describe the pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy (IMRT) for oropharyngeal cancer. "
5.	Adjuvant Radiotherapy 11/09/2010 - "HPV status predicts better outcome in oropharyngeal cancer treated with surgery plus adjuvant radiotherapy as well as with definitive radiation therapy±chemotherapy." 01/01/2014 - "Over the years, the treatment of oropharyngeal cancer has changed; in the past, first-line treatment consisted of surgery followed by adjuvant radiotherapy, today however, primary treatment typically involves concomitant chemoradiation, and reserves surgery for salvage. " 05/01/2011 - "The study population was selected from 195 patients with high-risk oral cavity or oropharyngeal cancer, who had either adjuvant radiotherapy (RT) or radiochemotherapy (RCT) between January 1, 1997 and December 31, 2006, at the University Clinic of Radiation Oncology of the Martin-Luther-University Halle-Wittenberg. " 07/01/2007 - "The aim of this study was to analyze swallowing outcome in advanced oral/oropharyngeal cancer patients treated with microvascular reconstructive surgery and adjuvant radiotherapy. " 09/01/2005 - "The aim of the study was to analyze speech outcome for patients with advanced oral/oropharyngeal cancer treated with reconstructive surgery and adjuvant radiotherapy. "